COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 studiesc19budesonide.com Aug 29, 2021Tau​2​ = 0.32; I​2​ = 43.4%; Z = 1.65Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Yu (RCT)39%0.61 [0.22-1.67]6/78710/799Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies39%0.61 [0.22-1.67]6/78710/79939% improvement1 budesonide COVID-19 mortality resultc19budesonide.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.96Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Yu (RCT)52%0.48 [0.23-1.01]10/77121/779Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment52%0.48 [0.23-1.01]10/77121/77952% improvementAll studies52%0.48 [0.23-1.01]10/77121/77952% improvement1 budesonide COVID-19 ICU resultc19budesonide.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 1.93Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 serious outcomesc19budesonide.com Aug 29, 2021Tau​2​ = 0.32; I​2​ = 43.4%; Z = 1.65Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 Randomized Controlled Trialsc19budesonide.com Aug 29, 2021Tau​2​ = 0.32; I​2​ = 43.4%; Z = 1.65Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Yu (RCT)39%0.61 [0.22-1.67]6/78710/799Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies39%0.61 [0.22-1.67]6/78710/79939% improvement1 budesonide COVID-19 RCT mortality resultc19budesonide.com Aug 29, 2021Tau​2​ = 0.00; I​2​ = 0.0%; Z = 0.96Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Early treatment82%0.18 [0.04-0.79]2/7311/7382% improvementYu (RCT)39%0.61 [0.22-1.67]death6/78710/799Improvement, RR [CI]TreatmentControlTau​2​ = 0.00; I​2​ = 0.0%Late treatment39%0.61 [0.22-1.67]6/78710/79939% improvementAll studies62%0.38 [0.12-1.20]8/86021/87262% improvement2 budesonide COVID-19 peer reviewed trialsc19budesonide.com Aug 29, 2021Tau​2​ = 0.32; I​2​ = 43.4%; Z = 1.65Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ramakrishnan (RCT)82%0.18 [0.04-0.79]hosp./ER2/7311/73Improvement, RR [CI]TreatmentControlRamakrishnan (RCT)90%0.10 [0.01-0.75]hosp./ER1/7010/69Ramakrishnan (RCT)67%0.33 [0.15-0.72]no recov.7/7021/69Yu (RCT)39%0.61 [0.22-1.67]death6/78710/799Yu (RCT)6%0.94 [0.44-1.98]ventilation13/77614/784Yu (RCT)52%0.48 [0.23-1.01]ICU10/77121/779Yu (RCT)25%0.75 [0.55-1.03]hosp./death72/787116/1,069Yu (RCT)17%0.83 [0.74-0.93]recov. time787 (n)1,069 (n)budesonide COVID-19 outcomesc19budesonide.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home